Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $459.8 million.

  • Monte Rosa Therapeutics' Liabilities and Shareholders Equity rose 4594.42% to $459.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 3429.0%. This contributed to the annual value of $438.7 million for FY2024, which is 4443.61% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Liabilities and Shareholders Equity stood at $459.8 million, which was up 4594.42% from $359.6 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $459.8 million for Q3 2025, and its period low was $252.1 million during Q3 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Liabilities and Shareholders Equity averaged around $338.3 million, with its median value being $315.1 million (2024).
  • In the last 5 years, Monte Rosa Therapeutics' Liabilities and Shareholders Equity crashed by 1368.23% in 2024 and then skyrocketed by 4740.58% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Liabilities and Shareholders Equity stood at $303.8 million in 2023, then skyrocketed by 44.44% to $438.7 million in 2024, then increased by 4.81% to $459.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $459.8 million in Q3 2025, compared to $359.6 million in Q2 2025 and $393.2 million in Q1 2025.